Paramyxoviridae infectious disease
Therapeutic area
Infectious Disease
Rare disease
No
- Definition
- Infections with viruses of the family paramyxoviridae. This includes morbillivirus infections; respirovirus infections; pneumovirus infections; henipavirus infections; avulavirus infections; and rubulavirus infections.
- Genetic basis
- No
- Non-human condition
- No
- Rare disease
- No
- Listing at source
- Listed
- Condition name
- Paramyxoviridae infectious disease
- Therapeutic area
- Infectious Disease
- Paramyxoviridae infectious disease
- Paramyxoviridae caused disease or disorder
- Paramyxoviridae disease or disorder
- Disease mechanisms
- Acquired
- All therapeutic areas
- Infectious Disease
- Severity
- Unknown
- MONDO ID
- MONDO:0005896
- Parent condition
- MONDO:0005856
Related records
Broader conditions (8)
- Disease
- Disease by etiologic mechanism
- Disease of primarily extrinsic mechanism
- Human disease
- Infectious disease
- Mononegavirales infectious disease
- Primary viral infectious disease
- Viral infectious disease
Narrower conditions (15)
- Avulavirus infectious disease
- Congenital mumps
- Fetal parainfluenza virus type 3 syndrome
- Hendra virus infection
- Henipavirus infectious disease
- Measles
- Morbillivirus infectious disease
- Mumps infectious disease
- Nipah virus disease
- Parainfluenza infectious disease
- Parainfluenza virus type 1 infectious disease
- Parainfluenza virus type 2 infectious disease
- Parainfluenza virus type 3 infectious disease
- Parainfluenza virus type 4 infectious disease
- Respirovirus infectious disease
Trials (25)
- A Phase 1 Study to Evaluate Safety & Immunogenicity of RVSV-Nipah Virus Vaccine Candidate PHV02 in Healthy Adult Subjects
- A Phase II, Randomized, Double-blind, Placebo-controlled Study to Examine the Effects of DAS181 in Immunocompromised Subjects With Lower Respiratory Tract Parainfluenza Infection on Supplemental Oxygen
- A Study on the Safety and Immunogenicity of Influenza, Respiratory Syncytial Virus, Human Metapneumovirus and Parainfluenza Vaccines in Adults 18 to 49 Years of Age.
- A Study to Assess the Safety of Live Intranasal Sendai Virus Vaccine in Children and Toddlers
- An Open Label Study to Examine the Effects of DAS181 Administered by Dry Powder Inhaler (DPI) or Nebulized Formulation in Immunocompromised Subjects With Parainfluenza (PIV) Infection
- Clinical Features, Outcome and Prognosis of Human Metapneumovirus (hMPV) Lower Respiratory Tract Infections in Adult Inpatients
- Collection and Testing of Respiratory Samples
- DAS181 in Patients With Parainfluenza
- LIAISON NES Influenza (FLU) A/B, Respiratory Syncytial Virus (RSV), & Coronavirus Disease 2019 (COVID-19) in Symptomatic Patients in Australia
- Phase 1 Safety and Pharmacokinetics Study of Single Ascending Doses of BTA-C585 in Healthy Volunteers
- Phase 2 Study of Inhaled SNG001 in Mechanically Ventilated Patients With Respiratory Viral Infection
- Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study
- Safety and Immunogenicity of mRNA-1653, a Combined Human Metapneumovirus (hMPV) and Parainfluenza Virus Type 3 (PIV3) Vaccine, in Healthy Adults, and Children 12 to 59 Months of Age With Serologic Evidence of Prior Exposure
- Safety and Immunogenicity Study of SCB-1022 and SCB-1033 in Healthy Older Adults
- Safety and Pharmacokinetics Study of Multiple Ascending Doses of BTA-C585 in Healthy Volunteers
- Safety of and Immune Response to a Cow/Human Parainfluenza Virus Vaccine (rB/HPIV3) in Healthy Infants, Children, and Adults
- Safety of and Immune Response to a Human Parainfluenza Virus Vaccine (rHPIV3cp45) in Healthy Infants
- Safety of and Immune Response to Recombinant Live Attenuated Parainfluenza Type 3 Virus Vaccine in Healthy Infants and Children
- Safety of and Immune Response to Recombinant Live-Attenuated Parainfluenza Type 1 Virus Vaccine
- Safety, Efficacy and Pharmacokinetics of BTA-C585 in a RSV Viral Challenge Study
Drugs in development (2)
- DAS-181 Phase 3
- Lactose, anhydrous Phase 2